• In patients with a prior CV event who needed more additional lipid-lowering, the 75 mg Praluent® dose was used 78% of the time in the ODYSSEY OUTCOMES study1

    Customized treatment with Praluent®

    Dosage information2

    The dose of Praluent® can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). If additional LDL-C reduction is needed in patients treated with 75 mg Q2W or 300 mg once Q4W (monthly), the dosage may be adjusted to the maximum dosage of 150 mg Q2W.

    If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.

    PRALUENT INDICATION

    Learn more

    HOW TO INJECT PRALUENT

    Learn more

    CV=cardiovascular; LDL-C=low-density lipoprotein cholesterol; Q2W=once every two weeks; Q4W=once every four weeks.

    1. Schwartz G, et al. N Engl J Med 2018;379:2097–2107. Supplementary Appendix.
    2. Praluent® (alirocumab) European Summary of Product Characteristics. March 2019.